Confocal Fluorescence Spectroscopy for Cell-Free DNA Integrity Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing cell-free nucleic acids (CNAs) for cancer detection, such as PCR-based techniques, face challenges including low concentrations, difficulty in discerning relevant biomarkers from background noise, and require complex and costly processes, limiting their clinical utility.
Innovation Solution
The development of microfluidic cylindrical illumination confocal spectroscopy (μCICS) for direct analysis of DNA integrity in cell-free nucleic acids, which uses fluorescent burst sizing to determine DNA size and distribution without the need for enzymatic amplification, enabling high sensitivity and specificity in cancer detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR-based methods are used to analyze cell-free nucleic acids, then sensitivity is improved, but device complexity and cost increase
Solution Approach 1:
The patent replaces the complex enzymatic PCR system with a direct optical detection system using confocal microscopy. Instead of using polymerase enzymes and thermal cycling, the method directly visualizes and counts fluorescently labeled DNA molecules in cell-free nucleic acid samples, eliminating the need for complex enzymatic processes while maintaining sensitivity.
Solution Approach 2:
The patent extracts and directly analyzes the DNA molecules of interest from the complex background of cell-free nucleic acids using fluorescence-based techniques. By using fluorescent dyes that specifically bind to DNA and confocal microscopy to detect them, the method separates the signal from background noise without requiring amplification, thus reducing complexity while maintaining detection capability.
2Measurement precision
If PCR-based methods are used to analyze cell-free nucleic acids, then detection capability is improved, but analysis time increases
Solution Approach 1:
The patent skips the time-consuming PCR amplification steps by directly detecting fluorescently labeled DNA molecules. Instead of undergoing multiple cycles of denaturation, annealing, and extension, the method directly visualizes and counts DNA molecules in cell-free nucleic acid samples, dramatically reducing analysis time while maintaining detection capability.
Solution Approach 2:
The patent performs preliminary labeling of DNA molecules with fluorescent dyes before analysis. This preliminary action allows for direct detection without requiring time-consuming amplification steps, as the fluorescent labels are already in place to enable immediate visualization and counting using confocal microscopy.
3Measurement precision
If PCR-based methods are used to analyze cell-free nucleic acids, then quantification capability is improved, but reliability decreases due to optimization requirements
Solution Approach 1:
The patent replaces the enzyme-based PCR system with a direct optical detection system. By using confocal microscopy to directly count and measure fluorescently labeled DNA molecules, the method eliminates the need for enzymatic optimization and thermal cycling parameters, resulting in more reliable and reproducible quantification that does not depend on finicky enzymatic conditions.
Solution Approach 2:
The patent uses the DNA molecules themselves as the detection target, labeled with fluorescent dyes that provide their own signal. This self-service approach eliminates the need for external enzymatic amplification and optimization, allowing direct quantification based on the inherent fluorescent signal from the labeled DNA, thereby improving reliability and reducing dependence on optimized enzymatic conditions.
4Reliability
If conventional methods are used for cancer detection, then current standards are maintained, but detection stage is worsened (later stage detection)
Solution Approach 1:
The patent extracts and directly analyzes DNA integrity information from cell-free nucleic acids in body fluids. By using confocal microscopy to visualize and measure DNA fragment size distributions, the method can detect cancer-related changes in DNA integrity before conventional methods would detect them, enabling earlier stage detection while maintaining analytical reliability.
Solution Approach 2:
The patent changes the detection parameter from traditional tumor mass or biomarker detection to DNA integrity analysis. By measuring changes in DNA fragment size distribution and integrity parameters in cell-free nucleic acids, the method can detect cancer at earlier stages before conventional methods become positive, effectively shifting the detection timeline while maintaining diagnostic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
μCICS provides a rapid, economical, and accurate method for cancer detection, capable of analyzing DNA integrity in serum samples without DNA isolation or PCR amplification, offering high sensitivity and specificity, and can detect cancers at an earlier stage than conventional methods.
Implementation Method 1
The DNA molecules in a CNA sample of interest are labeled in a stoichiometric manner with a fluorescent dye, such that the amount of label is proportional to the length of the DNA molecules, and fluorescence burst parameters are measured
Data Source
AI summary
The present invention relates, e.g., to a method for determining the size distribution of DNA molecules in a sample comprising cell-free nucleic acid, comprising labeling the DNA with a fluorescent dye in a stoichiometric manner, subjecting the DNA to molecular spectroscopy (e.g., cylindrical illumination confocal spectroscopy), analyzing suitable fluorescent burst parameters of the labeled DNA, and conducting single molecule DNA integrity analysis of the labeled DNA molecules in the sample. In one embodiment of the invention, the method is used as a diagnostic method for detecting cancer.